QQQ   424.90 (-0.22%)
AAPL   167.43 (-0.34%)
MSFT   407.65 (-1.02%)
META   504.01 (+1.99%)
GOOGL   155.10 (-0.24%)
AMZN   180.29 (-0.55%)
TSLA   149.30 (-3.96%)
NVDA   842.72 (+0.28%)
AMD   154.34 (+0.21%)
NIO   3.91 (+0.00%)
BABA   69.15 (+0.48%)
T   16.16 (+0.25%)
F   12.04 (+0.00%)
MU   116.24 (-0.08%)
GE   157.24 (+1.01%)
CGC   6.58 (+1.39%)
DIS   112.92 (-0.02%)
AMC   2.77 (-7.05%)
PFE   25.39 (-0.12%)
PYPL   62.99 (-0.43%)
XOM   118.84 (+0.18%)
QQQ   424.90 (-0.22%)
AAPL   167.43 (-0.34%)
MSFT   407.65 (-1.02%)
META   504.01 (+1.99%)
GOOGL   155.10 (-0.24%)
AMZN   180.29 (-0.55%)
TSLA   149.30 (-3.96%)
NVDA   842.72 (+0.28%)
AMD   154.34 (+0.21%)
NIO   3.91 (+0.00%)
BABA   69.15 (+0.48%)
T   16.16 (+0.25%)
F   12.04 (+0.00%)
MU   116.24 (-0.08%)
GE   157.24 (+1.01%)
CGC   6.58 (+1.39%)
DIS   112.92 (-0.02%)
AMC   2.77 (-7.05%)
PFE   25.39 (-0.12%)
PYPL   62.99 (-0.43%)
XOM   118.84 (+0.18%)
QQQ   424.90 (-0.22%)
AAPL   167.43 (-0.34%)
MSFT   407.65 (-1.02%)
META   504.01 (+1.99%)
GOOGL   155.10 (-0.24%)
AMZN   180.29 (-0.55%)
TSLA   149.30 (-3.96%)
NVDA   842.72 (+0.28%)
AMD   154.34 (+0.21%)
NIO   3.91 (+0.00%)
BABA   69.15 (+0.48%)
T   16.16 (+0.25%)
F   12.04 (+0.00%)
MU   116.24 (-0.08%)
GE   157.24 (+1.01%)
CGC   6.58 (+1.39%)
DIS   112.92 (-0.02%)
AMC   2.77 (-7.05%)
PFE   25.39 (-0.12%)
PYPL   62.99 (-0.43%)
XOM   118.84 (+0.18%)
QQQ   424.90 (-0.22%)
AAPL   167.43 (-0.34%)
MSFT   407.65 (-1.02%)
META   504.01 (+1.99%)
GOOGL   155.10 (-0.24%)
AMZN   180.29 (-0.55%)
TSLA   149.30 (-3.96%)
NVDA   842.72 (+0.28%)
AMD   154.34 (+0.21%)
NIO   3.91 (+0.00%)
BABA   69.15 (+0.48%)
T   16.16 (+0.25%)
F   12.04 (+0.00%)
MU   116.24 (-0.08%)
GE   157.24 (+1.01%)
CGC   6.58 (+1.39%)
DIS   112.92 (-0.02%)
AMC   2.77 (-7.05%)
PFE   25.39 (-0.12%)
PYPL   62.99 (-0.43%)
XOM   118.84 (+0.18%)
OTCMKTS:OSIR

Osiris Therapeutics (OSIR) Stock Price, News & Analysis

$18.99
0.00 (0.00%)
(As of 04/17/2019)
Today's Range
$18.99
$18.99
50-Day Range
$18.99
$18.99
52-Week Range
$7.01
$19.30
Volume
N/A
Average Volume
205,753 shs
Market Capitalization
$655.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
OSIR stock logo

About Osiris Therapeutics Stock (OTCMKTS:OSIR)

Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

OSIR Stock Price History

OSIR Stock News Headlines

Kanak Kanti
IRS Loophole Gives Americans An Escape From Inflation
In the years immediately following 2008-09, as the economy stagnated, gold exploded in value. Today, Goldman Sachs is telling its clients that gold may reach $2,250 within the next few years. Don't miss your chance to diversify your savings.
IRS Loophole Gives Americans An Escape From Inflation
In the years immediately following 2008-09, as the economy stagnated, gold exploded in value. Today, Goldman Sachs is telling its clients that gold may reach $2,250 within the next few years. Don't miss your chance to diversify your savings.
Watch NASA reveal its Bennu asteroid samples at 11AM ET
Amniotic Membrane Global Market Report 2023
Tissue Engineering Global Market Report 2023
Vesselon Discovery Protects and Expands Drug Franchises
See More Headlines
Receive OSIR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Osiris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
Biotechnology
Current Symbol
OTCMKTS:OSIR
Previous Symbol
NASDAQ:OSIR
CUSIP
68827R10
Fax
N/A
Employees
N/A
Year Founded
1992

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$655.69 million
Optionable
Not Optionable
Beta
N/A

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Jason Keefer (Age 46)
    Interim Pres & CEO
  • Dr. Alla N. Danilkovitch (Age 54)
    Chief Scientific Officer
  • Mr. Joel David Rogers (Age 56)
    Interim Chief Financial Officer
  • Mr. Edward Yip
    Chief Legal Officer & Corp. Sec.
  • Mr. Laine Dyess
    VP of Sales

OSIR Stock Analysis - Frequently Asked Questions

How have OSIR shares performed in 2024?

Osiris Therapeutics' stock was trading at $18.99 at the start of the year. Since then, OSIR shares have increased by 0.0% and is now trading at $18.99.
View the best growth stocks for 2024 here
.

What other stocks do shareholders of Osiris Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Osiris Therapeutics investors own include Sierra Wireless (SWIR), Achillion Pharmaceuticals (ACHN), Fate Therapeutics (FATE), Ionis Pharmaceuticals (IONS), Mallinckrodt (MNK), Aerie Pharmaceuticals (AERI), Cytokinetics (CYTK) and Depomed (DEPO).

How do I buy shares of Osiris Therapeutics?

Shares of OSIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:OSIR) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners